| Literature DB >> 19415537 |
Tomonobu Koizumi1, Toshihiko Agatsuma, Takashi Ichiyama, Toshiki Yokoyama, Atsuhito Ushiki, Yoshimichi Komatsu, Tsuyoshi Tanabe, Takashi Kobayashi, Sumiko Yoshikawa, Masanori Yasuo, Hiroshi Yamamoto, Keishi Kubo, Tsutomu Hachiya.
Abstract
It has been reported that cisplatin-based chemotherapy shows beneficial effects in certain patients with advanced thymic carcinoma. However, the usefulness of salvage therapy has not been reported. We focused on a new anthracycline agent, amrubicin, combined with platinum compounds as salvage chemotherapy in patients with thymic carcinoma. Six cases of unresectable and locally advanced thymic carcinoma relapsed from prior cisplatin-containing chemotherapy were treated with amrubicin (30-40 mg/m(2) day 1-3) plus platinum compounds (cisplatin 60 mg/m(2) day 1 or nedaplatin 70 mg/m(2) day 1) chemotherapy as salvage chemotherapy. Two patients showed a partial response. However, Grade 3/4 neutropenia and thrombocytopenia occurred in all and two of the patients, respectively. We conclude that thymic carcinoma is sensitive to platinum-based chemotherapy and that amrubicin appears to have significant activity against thymic carcinoma. The major toxicity is hematological toxicities.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19415537 DOI： 10.1007/s12032-009-9223-y
Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064